A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome
Sign Up to like & getrecommendations! Published in 2022 at "JCI Insight"
DOI: 10.1172/jci.insight.163030
Abstract: BACKGROUND Primary Sjögren’s syndrome (pSS) is characterized by B cell hyperactivity and elevated B-lymphocyte stimulator (BLyS). Anti-BLyS treatment (e.g., belimumab) increases peripheral memory B cells; decreases naive, activated, and plasma B cell subsets; and increases… read more here.
Keywords: primary gren; gren syndrome; belimumab rituximab; sequential belimumab ... See more keywords
Low Peripheral B-Cell Counts in Patients With Systemic Rheumatic Diseases Due to Treatment With Belimumab and/or Rituximab Are Associated With Low Antibody Responses to Primary COVID-19 Vaccination
Sign Up to like & getrecommendations! Published in 2022 at "HSS Journal"
DOI: 10.1177/15563316221142846
Abstract: Background: Immunosuppressive agents inhibit COVID-19 vaccine antibody (Ab) responses in patients with systemic rheumatic diseases. Rituximab may fully block Ab responses when B cells become undetected. The effect of detected but low number of B… read more here.
Keywords: cell; rheumatic diseases; belimumab rituximab; cell counts ... See more keywords
Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Internal Medicine"
DOI: 10.7326/m21-2078
Abstract: BACKGROUND B-cell depletion with rituximab is commonly used for patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable responses. We hypothesized that high B-cell activating factor (BAFF) levels… read more here.
Keywords: lupus erythematosus; sle refractory; belimumab rituximab; systemic lupus ... See more keywords